🚀 VC round data is live in beta, check it out!
Kissei Pharmaceutical Valuation Multiples
Discover revenue and EBITDA valuation multiples for Kissei Pharmaceutical and similar public comparables like DBV Technologies, MapLight Therapeutics, Uniphar, GuangYuYuan Chinese and more.
Kissei Pharmaceutical Overview
About Kissei Pharmaceutical
Kissei Pharmaceutical Co Ltd is a specialty and generic drug manufacturing company. Pharmaceuticals is the company's reportable segment. The company’s operations span across the globe, while the vast majority of revenue is generated in Japan, followed by Europe. Kissei operates a variety of subsidiaries. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
Founded
1946
HQ
Employees
2.1K
Website
Sectors
Financials (LTM)
EV
$978M
Kissei Pharmaceutical Financials
Kissei Pharmaceutical reported last 12-month revenue of $611M and EBITDA of $47M.
In the same LTM period, Kissei Pharmaceutical generated $294M in gross profit, $47M in EBITDA, and $82M in net income.
Revenue (LTM)
Kissei Pharmaceutical P&L
In the most recent fiscal year, Kissei Pharmaceutical reported revenue of $609M and EBITDA of $128M.
Kissei Pharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $611M | XXX | $609M | XXX | XXX | XXX |
| Gross Profit | $294M | XXX | $278M | XXX | XXX | XXX |
| Gross Margin | 48% | XXX | 46% | XXX | XXX | XXX |
| EBITDA | $47M | XXX | $128M | XXX | XXX | XXX |
| EBITDA Margin | 8% | XXX | 21% | XXX | XXX | XXX |
| EBIT Margin | (2%) | XXX | 7% | XXX | XXX | XXX |
| Net Profit | $82M | XXX | $82M | XXX | XXX | XXX |
| Net Margin | 13% | XXX | 14% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Kissei Pharmaceutical Stock Performance
Kissei Pharmaceutical has current market cap of $1B, and enterprise value of $978M.
Market Cap Evolution
Kissei Pharmaceutical's stock price is $30.51.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $978M | $1B | 0.3% | XXX | XXX | XXX | $1.99 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialKissei Pharmaceutical Valuation Multiples
Kissei Pharmaceutical trades at 1.6x EV/Revenue multiple, and 21.0x EV/EBITDA.
EV / Revenue (LTM)
Kissei Pharmaceutical Financial Valuation Multiples
As of April 19, 2026, Kissei Pharmaceutical has market cap of $1B and EV of $978M.
Equity research analysts estimate Kissei Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Kissei Pharmaceutical has a P/E ratio of 15.4x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV (current) | $978M | XXX | $978M | XXX | XXX | XXX |
| EV/Revenue | 1.6x | XXX | 1.6x | XXX | XXX | XXX |
| EV/EBITDA | 21.0x | XXX | 7.7x | XXX | XXX | XXX |
| EV/EBIT | (86.0x) | XXX | 24.6x | XXX | XXX | XXX |
| EV/Gross Profit | 3.3x | XXX | 3.5x | XXX | XXX | XXX |
| P/E | 15.4x | XXX | 15.3x | XXX | XXX | XXX |
| EV/FCF | 12.3x | XXX | 12.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Kissei Pharmaceutical Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Kissei Pharmaceutical Margins & Growth Rates
Kissei Pharmaceutical's revenue in the last 12 month grew by 1%.
Kissei Pharmaceutical's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Kissei Pharmaceutical's rule of 40 is 16% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Kissei Pharmaceutical's rule of X is 21% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Kissei Pharmaceutical Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 1% | XXX | 0% | XXX | XXX | XXX |
| EBITDA Margin | 8% | XXX | 21% | XXX | XXX | XXX |
| EBITDA Growth | 97% | XXX | (65%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 16% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 21% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 0% | XXX | 0% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 23% | XXX | 15% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 40% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Kissei Pharmaceutical Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Kissei Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| DBV Technologies | XXX | XXX | XXX | XXX | XXX | XXX |
| MapLight Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Uniphar | XXX | XXX | XXX | XXX | XXX | XXX |
| GuangYuYuan Chinese | XXX | XXX | XXX | XXX | XXX | XXX |
| EyePoint | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Kissei Pharmaceutical M&A Activity
Kissei Pharmaceutical acquired XXX companies to date.
Last acquisition by Kissei Pharmaceutical was on XXXXXXXX, XXXXX. Kissei Pharmaceutical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Kissei Pharmaceutical
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialKissei Pharmaceutical Investment Activity
Kissei Pharmaceutical invested in XXX companies to date.
Kissei Pharmaceutical made its latest investment on XXXXXXXX, XXXXX. Kissei Pharmaceutical invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Kissei Pharmaceutical
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Kissei Pharmaceutical
| When was Kissei Pharmaceutical founded? | Kissei Pharmaceutical was founded in 1946. |
| Where is Kissei Pharmaceutical headquartered? | Kissei Pharmaceutical is headquartered in Japan. |
| How many employees does Kissei Pharmaceutical have? | As of today, Kissei Pharmaceutical has over 2K employees. |
| Who is the CEO of Kissei Pharmaceutical? | Kissei Pharmaceutical's CEO is Mutsuo Kanzawa. |
| Is Kissei Pharmaceutical publicly listed? | Yes, Kissei Pharmaceutical is a public company listed on Tokyo Stock Exchange. |
| What is the stock symbol of Kissei Pharmaceutical? | Kissei Pharmaceutical trades under 4547 ticker. |
| When did Kissei Pharmaceutical go public? | Kissei Pharmaceutical went public in 1988. |
| Who are competitors of Kissei Pharmaceutical? | Kissei Pharmaceutical main competitors are DBV Technologies, MapLight Therapeutics, Uniphar, GuangYuYuan Chinese. |
| What is the current market cap of Kissei Pharmaceutical? | Kissei Pharmaceutical's current market cap is $1B. |
| What is the current revenue of Kissei Pharmaceutical? | Kissei Pharmaceutical's last 12 months revenue is $611M. |
| What is the current revenue growth of Kissei Pharmaceutical? | Kissei Pharmaceutical revenue growth (NTM/LTM) is 1%. |
| What is the current EV/Revenue multiple of Kissei Pharmaceutical? | Current revenue multiple of Kissei Pharmaceutical is 1.6x. |
| Is Kissei Pharmaceutical profitable? | Yes, Kissei Pharmaceutical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Kissei Pharmaceutical? | Kissei Pharmaceutical's last 12 months EBITDA is $47M. |
| What is Kissei Pharmaceutical's EBITDA margin? | Kissei Pharmaceutical's last 12 months EBITDA margin is 8%. |
| What is the current EV/EBITDA multiple of Kissei Pharmaceutical? | Current EBITDA multiple of Kissei Pharmaceutical is 21.0x. |
| What is the current FCF of Kissei Pharmaceutical? | Kissei Pharmaceutical's last 12 months FCF is $79M. |
| What is Kissei Pharmaceutical's FCF margin? | Kissei Pharmaceutical's last 12 months FCF margin is 13%. |
| What is the current EV/FCF multiple of Kissei Pharmaceutical? | Current FCF multiple of Kissei Pharmaceutical is 12.3x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.